Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide rollover protocol for patients continuing benefit after prior Novartis pasireotide studies
2013-000267-84Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pasireotide LAR in Corticotropin adenoma (ACTHoma) and apudoma (NET), sponsored by Novartis. Primary endpoint: Number of patients receiving pasireotide. Started Apr 2013; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)apudoma (NET)
Beyond the preview
Go deeper on 2013-000267-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000267-84.